A Canadian COVID-19 Vaccine Is Showing 'Promising Results' In Its Early Trials

A COVID-19 vaccine in Canada could be on the horizon! A Quebec-based company is reporting “promising results” from their vaccine candidate, which is currently in its early trial stages.

In a statement shared on November 10, Canadian company Medicago confirmed that their Phase 1 clinical trials had been going pretty well.

According their results so far, 100% of the volunteers developed a “promising antibody response” after two doses of the plant-derived shot.

Editor's Choice: Trudeau Says Canadians Can Be 'Quite Certain' The US Election Result Is Accurate

These are very promising results. Medicago

As part of Phase 1, the trial included 190 healthy participants between the ages of 18 and 55. 

“There were no severe adverse events reported and reactogenicity events were generally mild to moderate and short in duration,” the company added.

In fact, CTV News reports that those who received the Medicago adjuvanted vaccine ended up with higher antibody levels than those who had actually contracted COVID-19.

This comes just one day after American company Pfizer confirmed their vaccine candidate was up to 90% effective at preventing the illness.

Speaking about this development on Monday, Trudeau confirmed that Canada had already of Pfizer's potential shot.

The PM also said he hoped COVID-19 vaccinations would arrive in the country by early 2021.